Order Article Reprints

Chouaid C, Thomas M, Debieuvre D, Durand-Zaleski I, Zacharias S, Bosquet L, Groth A, Fleitz A, Calleja A, Patel S, et al. Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts. Cancers. 2022; 14(24):6148. https://doi.org/10.3390/cancers14246148

Chouaid, Christos, Michael Thomas, Didier Debieuvre, Isabelle Durand-Zaleski, Stefan Zacharias, Lise Bosquet, Annika Groth, Annette Fleitz, Alan Calleja, Sonya Patel, and et al. 2022. "Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts" Cancers 14, no. 24: 6148. https://doi.org/10.3390/cancers14246148

Chouaid, C., Thomas, M., Debieuvre, D., Durand-Zaleski, I., Zacharias, S., Bosquet, L., Groth, A., Fleitz, A., Calleja, A., Patel, S., Lacoin, L., Daumont, M. J., Penrod, J. R., Carroll, R., Waldenberger, D., Cotté, F.-E., Audigier-Valette, C., & Griesinger, F. (2022). Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts. Cancers, 14(24), 6148. https://doi.org/10.3390/cancers14246148